FDA Needs Additional Time to Review Sparsentan, Tofersen Applications

The Food and Drug Administration (FDA) has extended the review periods for 2 investigational products: sparsentan and tofersen.

Related Keywords

Deric Dube ,Priya Singhal ,Regulatory Sciences ,Drug Administration ,Priority Review ,New Drug Application ,Prescription Drug User Fee Act ,Travere Therapeutics ,Risk Evaluation Mitigation Strategy ,Global Safety ,Interim Head ,